Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0001968202-24-000025 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-04 | 2024-01-02 | REGN | RYAN ARTHUR F | Dir | S - Sale | $899.90 | -100 | 18.4K | -0.5% | -$90.0K |
| D | 2024-01-04 | 2024-01-02 | REGN | RYAN ARTHUR F | Dir | A - Grant | $0.00 | +135 | 18.5K | +0.7% | $0 |
| D | 2024-01-04 | 2024-01-02 | REGN | RYAN ARTHUR F | Dir | A - Grant | $0.00 | +1,607 | 1,607 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | S | D | 6 | $898.76 | 18,425 | D | — | — | (F4) Represents volume-weighted average price of sales of 6 shares of Company stock on January 2, 2024 at prices ranging from $898.45 to $898.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. |
| 2 | Common | Common Stock | 2024-01-02 | S | D | 1 | $873.91 | 18,446 | D | — | — | |
| 3 | Common | Common Stock | 2024-01-02 | S | D | 29 | $900.59 | 18,382 | D | — | — | (F6) Represents volume-weighted average price of sales of 29 shares of Company stock on January 2, 2024 at prices ranging from $900.00 to $900.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. |
| 4 | Common | Common Stock | 2024-01-02 | S | D | 9 | $901.46 | 18,373 | D | — | — | (F7) Represents volume-weighted average price of sales of 9 shares of Company stock on January 2, 2024 at prices ranging from $901.03 to $901.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. |
| 5 | Common | Common Stock | 2024-01-02 | S | D | 10 | $902.37 | 18,363 | D | — | — | (F8) Represents volume-weighted average price of sales of 10 shares of Company stock on January 2, 2024 at prices ranging from $902.14 to $902.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. |
| 6 | Common | Common Stock | 2024-01-02 | S | D | 13 | $903.49 | 18,350 | D | — | — | (F9) Represents volume-weighted average price of sales of 13 shares of Company stock on January 2, 2024 at prices ranging from $903.13 to $903.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. |
| 7 | Common | Common Stock | 2024-01-02 | S | D | 3 | $904.49 | 18,347 | D | — | — | (F10) Represents volume-weighted average price of sales of 3 shares of Company stock on January 2, 2024 at prices ranging from $904.00 to $904.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. |
| 8 | Common | Common Stock | 2024-01-02 | A | A | 135 | $0.00 | 18,482 | D | — | — | |
| 9 | Common | Common Stock | 2024-01-02 | S | D | 8 | $896.47 | 18,434 | D | — | — | (F2) Represents volume-weighted average price of sales of 8 shares of Company stock on January 2, 2024 at prices ranging from $896.21 to $896.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. |
| 10 | Common | Common Stock | 2024-01-02 | S | D | 1 | $892.00 | 18,442 | D | — | — | |
| 11 | Common | Common Stock | 2024-01-02 | S | D | 3 | $897.41 | 18,431 | D | — | — | (F3) Represents volume-weighted average price of sales of 3 shares of Company stock on January 2, 2024 at prices ranging from $897.35 to $897.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. |
| 12 | Common | Common Stock | 2024-01-02 | S | D | 1 | $887.13 | 18,443 | D | — | — | |
| 13 | Common | Common Stock | 2024-01-02 | S | D | 2 | $886.26 | 18,444 | D | — | — | |
| 14 | Common | Common Stock | 2024-01-02 | S | D | 14 | $899.66 | 18,411 | D | — | — | (F5) Represents volume-weighted average price of sales of 14 shares of Company stock on January 2, 2024 at prices ranging from $899.08 to $899.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2024 at each separate price. |
| 15 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-02 | A | A | 1,607 | $0.00 | 1,607 | D | $888.34 · — to 2034-01-02 | 1,607 Common Stock | (F12) On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |